Navigation Links
Takeda Announces PDUFA Action Date for Investigational Type 2 Diabetes Therapies Alogliptin and the Fixed-Dose Combination Alogliptin/Pioglitazone
Date:11/1/2011

DEERFIELD, Ill., Nov. 1, 2011 /PRNewswire/ -- Takeda Global Research & Development Center, Inc., (Takeda) announced that the U.S. Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) action date of January 25, 2012 for the review of its investigational type 2 diabetes therapy alogliptin, and the fixed-dose combination therapy alogliptin/pioglitazone, which combines alogliptin with pioglitazone in a single tablet.  

Currently, the FDA is reviewing the new drug applications (NDA) for the investigational therapies, which were resubmitted on July 25, 2011; the FDA has categorized these as Class 2 responses, requiring up to six months for review. Alogliptin is a selective dipeptidyl peptidase IV inhibitor (DPP-4i) under investigation in the United States (U.S.) for the treatment of type 2 diabetes as an adjunct to diet and exercise. Discovered by Takeda San Diego, Inc., alogliptin is designed to slow the inactivation of incretin hormones GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide), which play a role in regulating blood glucose levels. Pioglitazone was approved in 1999 for the treatment of type 2 diabetes as an adjunct to diet and exercise. If approved, alogliptin/pioglitazone will be the first type 2 diabetes treatment option in the U.S. to include both a DPP-4 inhibitor and a thiazolidinedione (TZD) in a single tablet.

According to the International Diabetes Federation, a staggering 285 million individuals were living with diabetes worldwide in 2010.

"As recent figures indicate that diabetes continues to be a serious global health challenge, Takeda remains deeply committed to researching new and important therapeutic options for patients living with type 2 diabetes," said David Recker, M.D., senior vice president, clinical science, Takeda Global Research & Development Center. "Phase 3 studies have demonstrated that the combination of a
'/>"/>

SOURCE Takeda Global Research & Development Center, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Takeda Initiates Phase 3 Clinical Trial Program in the United States, Latin America, and Europe for Investigational Type 2 Diabetes Therapy TAK-875
2. Takeda Completes Acquisition and Names New CEO of Nycomed
3. Amylin and Takeda Discontinue Development of Pramlintide/Metreleptin Combination Treatment for Obesity Following Commercial Reassessment of the Program
4. Takeda Resubmits New Drug Applications in the U.S. for Investigational Type 2 Diabetes Therapies Alogliptin and the Fixed-Dose Combination Alogliptin/Pioglitazone
5. Takeda Responds to U.S. Food and Drug Administration Update to Safety Review of ACTOS (pioglitazone HCl)
6. Takeda to Acquire Nycomed
7. Amylin and Takeda Voluntarily Suspend Clinical Activities in Obesity Trial
8. Intra-Cellular Therapies and Takeda Enter into Worldwide Collaboration to Develop and Commercialize Compounds for Schizophrenia
9. Handa Pharmaceuticals Announces Submission of Its First-to-File ANDA for Takedas DEXILANT®
10. Takeda Submits New Drug Application in the U.S. for Azilsartan Medoxomil Plus Chlorthalidone, an Investigational Fixed-Dose Combination for the Treatment of Hypertension
11. Takeda Enters Into Global Strategic Partnerships With Covance and Quintiles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)...   Hospira, Inc. (NYSE: HSP ... infusion technologies, today announced that the company will present ... Wednesday, Jan. 14, 2015, in San Francisco.  ... 10:30 a.m. Pacific time on Wednesday, Jan. 14, 2015.  ... a live audiocast accessible via the Investor Relations section ...
(Date:12/19/2014)... , December 18, 2014 ... software application/module that is used to store, manipulate, ... RIS comprises a patient tracking and scheduling system, ... integration of RIS with HIS and other databases ... patient registration and patient scheduling, patient list management, ...
(Date:12/19/2014)... 2014 Capnia, Inc. (NASDAQ: ... diagnostics based on its proprietary Sensalyze™ Technology Platform ... financial results for the third quarter and nine ... the completion of our initial public offering (IPO), ... recently initiated CoSense® commercial launch," said Anish Bhatnagar, ...
Breaking Medicine Technology:The Global Radiology Information Systems Market is Expected to Grow at a CAGR of 7.5% from 2014 to 2019 2The Global Radiology Information Systems Market is Expected to Grow at a CAGR of 7.5% from 2014 to 2019 3Capnia Reports Third Quarter 2014 Financial Results 2Capnia Reports Third Quarter 2014 Financial Results 3Capnia Reports Third Quarter 2014 Financial Results 4Capnia Reports Third Quarter 2014 Financial Results 5Capnia Reports Third Quarter 2014 Financial Results 6Capnia Reports Third Quarter 2014 Financial Results 7Capnia Reports Third Quarter 2014 Financial Results 8
... N.J.--(BUSINESS WIRE)--Jun 21, 2007 - Nymox,Pharmaceutical Corporation ... the Company's recently completed studies of,NX-1207 for ... at,a series of upcoming U.S. urology meetings, ... Urological Association Meeting in,Colorado Springs. These independent ...
... June 21, 2007 /PRNewswire/ -- , What and When , Data ... presented in poster format at the 67th,Scientific Sessions of the American ... serious adverse events in high-risk type 2, ... from, PROactive; Poster 0553-P presented ...
Cached Medicine Technology:Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S.,Urology Meetings 2MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating,MacroVascular Outcomes Presented at the American Diabetes,Association 67th Scientific Sessions 2MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating,MacroVascular Outcomes Presented at the American Diabetes,Association 67th Scientific Sessions 3
(Date:12/22/2014)... On December 22, 2014, My Positive Perspective ... for an episode to celebrate Christmas. At the beginning ... so important to you that we all appreciate and ... should respect who Jesus was. I think sometimes we ... That means that on Jesus’ birthday we remember that ...
(Date:12/22/2014)... China (PRWEB) December 22, 2014 Physicians ... MabThera (rituximab) for the treatment of non-Hodgkin’s lymphoma (NHL), ... , a leading global healthcare consulting firm. MabThera is ... lymphoma (DLBCL), the most common form of NHL. , ... Access and Barriers,” the incidence of NHL in China ...
(Date:12/22/2014)... Florida (PRWEB) December 22, 2014 Give ... holiday season, the gift of health and vitality. , ... offering its three top-selling anti-aging formulas in special Holiday ... free rush delivery. , Each bottle contains cutting-edge, ... areas that don't work as well as we age. ...
(Date:12/22/2014)... Texas (PRWEB) December 22, 2014 7,178 ... and bustle of Black Friday shopping and opted instead ... and marketing education company, for their 5th annual “Black ... charged just $7 to attend the 5 hour ... that they promptly donated to support two Central Texas ...
(Date:12/22/2014)... NY (PRWEB) December 22, 2014 ... a 2014 Professional Woman of the Year. She is ... As the largest, most recognized networking organization of professional ... profession, the National Association of Professional Women is a ... 300 Local Chapters. , Ms. Kreider is passionate and ...
Breaking Medicine News(10 mins):Health News:My Positive Perspective Celebrates Christmas With an Event to Celebrate the Birthday of Jesus 2Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 2Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 3Health News:You Still Have Time to Give the Gift of Health and Vitality to a Mature Loved One 2Health News:Austin Company Digital Marketer Raises 100K to Fight Childhood Cancer 2Health News:Austin Company Digital Marketer Raises 100K to Fight Childhood Cancer 3Health News:National Association of Professional Women Announces Cheryl A. Kreider, President / CEO of Kreider Health Solutions, LLC, a 2014 Professional Woman of the Year 2
... AHA Create a Unified National Acute Coronary Syndromes ... DALLAS, May 1 The American College of,Cardiology ... Heart Association,s Get With The Guidelines(SM),(GWTG)-Coronary Artery Disease ... create a national unified registry for measuring and,improving ...
... in Product Sales Driven by Robust Growth in Clinical ... ... record revenue of $44.8 million for the first quarter,of fiscal 2008, an increase ... was $1.9 million, or $(0.03) per share, on a,GAAP basis; first quarter net ...
... seed and oil company will focus on new business development ... ULTRA low linolenic, trans fat-free products., ... an,agreement with two key venture capital firms, securing $4 million ... soybean,products. Asoyia is the innovator and leader in developing and ...
... and elsewhere report what is believed to be the ... of heart tissue and the subsequent damage leading to ... findings from the Multiethnic Study of Atherosclerosis (MESA), to ... Journal of the American College of Cardiology, appear to ...
... HILL, N.C., May 1 Leading pharmaceutical,companies ... recruitment,is part of the critical path in ... Trial Excellence: The Science and Art of ... techniques,that speed clinical trial investigator recruitment and ...
... PHILADELPHIA May 1, 2008 Shire plc ... company, announced today that it will present key ... (ADHD) treatments, lisdexamfetamine dimesylate, methylphenidate transdermal system and ... extended release, at the American Psychiatric Association (APA) ...
Cached Medicine News:Health News:The American College of Cardiology Foundation's NCDR(R) and the American Heart Association's GWTG Join Forces to Fight Heart Attacks 2Health News:The American College of Cardiology Foundation's NCDR(R) and the American Heart Association's GWTG Join Forces to Fight Heart Attacks 3Health News:Cepheid Reports Record Revenue of $44.8 Million 2Health News:Cepheid Reports Record Revenue of $44.8 Million 3Health News:Cepheid Reports Record Revenue of $44.8 Million 4Health News:Cepheid Reports Record Revenue of $44.8 Million 5Health News:Cepheid Reports Record Revenue of $44.8 Million 6Health News:Cepheid Reports Record Revenue of $44.8 Million 7Health News:Cepheid Reports Record Revenue of $44.8 Million 8Health News:Cepheid Reports Record Revenue of $44.8 Million 9Health News:Cepheid Reports Record Revenue of $44.8 Million 10Health News:Asoyia Secures Venture Capital Funding 2Health News:Asoyia Secures Venture Capital Funding 3Health News:Study in 7,000 men and women ties obesity, inflammatory proteins to heart failure risk 2Health News:Study in 7,000 men and women ties obesity, inflammatory proteins to heart failure risk 3Health News:Strategies for Winning Clinical Investigators in a Competitive Marketplace 2Health News:Shire to present ADHD treatments scientific data at American Psychiatric Assoc. Meeting 2
... The AFX Lens is ... for use in an air-filled ... use as a primary air-fluid ... profile and sutureless design make ...
... 45° Prism is designed ... and are recommended for ... BRVO etc.) and Rhegmatogenus ... be used for panretinal ...
... Chalam Flat is designed for ... and induction of posterior vitreous ... for macula whole surgery, epiretinal ... tractional epiretinal membranes. Direct image ...
... magnification and increased stereopsis, the Central Retinal ... to the equatorial regions. The Central Retinal ... in membrane peeling in proliferative vitreoretinopathy extending ... The ACS Vitrectomy Lenses from Volk can ...
Medicine Products: